Skip to main content
. 2013 Jul 16;8(7):e68154. doi: 10.1371/journal.pone.0068154

Figure 1. Expression of the NTT-MMP-2/EGFP fusion protein in transgenic hearts.

Figure 1

I. Western blot (using anti-MMP-2 IgG) of ventricular mitochondrial lysates isolated from 2–3 progeny of three individual transgenic founder lines (3393, 3930 and 3941). The NTT-MMP-2/EGFP fusion protein has an apparent molecular mass of 92 kDa and there is evidence for proteolytic cleavage of the EGFP component in several of the hearts, leaving the 65 kDa NTT-MMP-2 protein intact (+C: recombinant NTT-MMP-2/EGFP fusion protein). II. Immunohistochemistry of wild type (WT, panel A) and transgenic (TG, panels B–C) ventricular sections probed with anti-EGFP antibody and examined using Nomarksi optics. Compared to the WT controls, immunostaining is present in dense clusters (green pseudocolor) extending longitudinally between the myofilaments. In addition, linear arrays of reaction product are present in a subsarcolemmal distribution (panel C, arrows) as well as perpendicularly across the long axis of individual cardiomyocytes (panel D, arrows). The staining distribution is consistent primarily with a mitochondrial localization of the NTT-MMP/EGFP protein. (Final magnification: A, B: X325; C: X600; D: X900).